Over the weekend, a federal judge made a pivotal ruling in the antitrust lawsuit brought by Particle Health against Epic, allowing significant claims to proceed while dismissing others that lacked merit.
Judge Naomi Buchwald of the Southern District of New York confirmed that three of Particle’s federal antitrust claims would advance, along with a claim concerning tortious interference with business contracts, marking a crucial moment for the digital health industry.
The data platform company Particle initiated the lawsuit against the electronic health record (EHR) giant Epic last September, following a prolonged dispute. The startup’s complaint asserts that Epic is abusing its market dominance to stifle competition within the payer platform sector.
The payer platform sector represents the growing market for digital platforms that enable payers to access and analyze patient data at scale, facilitating better care coordination, crafting population health programs, and enhancing claims processing efficiency.
Particle’s lawsuit claims that Epic is obstructing the startup’s ability to compete in this sector by preventing Particle clients from accessing critical data stored by Epic.
At the heart of the legal battle is Carequality, a national data exchange framework that Epic plays a significant role in managing. Particle depends on Carequality to obtain patient records for its clients, but it alleges that Epic has selectively limited its access, thereby cutting off a vital channel for clinical data.
Particle contends that Epic has exploited its influence over Carequality to skew the market in its favor, effectively sidelining competitors. They argue that this constitutes an “unprecedented” use of market power that hampers innovation and restricts payers’ access to essential patient records. The company further claims that Epic’s practices have led to clients terminating their contracts and have hindered the formation of new business relationships.
In her ruling on September 5, Judge Buchwald noted that Particle had provided sufficient evidence to support its allegations of Epic’s anticompetitive behavior, allowing the case to move forward rather than being dismissed outright at this preliminary juncture. However, she dismissed several claims, including those related to conspiracy, defamation, and trade libel.
CEO of Particle, Jason Prestinario, expressed his satisfaction with Buchwald’s ruling in a post on LinkedIn.
“While a few of the claims were not upheld, Epic’s motion to dismiss was DENIED concerning all three core monopolization antitrust claims. This marks a historic moment, as it is the first time an antitrust case against Epic has advanced this far. It represents a step toward a larger victory for enhancing patient care and empowering patients with greater control over their medical information,” he stated.
An Epic spokesperson communicated with MedCity News, indicating that the company anticipates the subsequent phase of the legal proceedings.
“The Court dismissed the majority of Particle’s claims, while acknowledging that Carequality’s ‘imposition of the corrective action plan [on Particle] was entirely reasonable.’ Epic is committed to protecting patient data privacy and looks forward to presenting evidence to succeed on the remaining claims,” the spokesperson remarked.
The next phase for both parties involves discovery, which could illuminate the enforcement of data sharing rules and reveal the implications for the future of payer platforms.
To stay updated on the latest in litigation, regulations, deals, and financial services trends, subscribe to Finance Docket, a collaboration between Breaking Media publications Above the Law and Dealbreaker.
